Dataset Information

The effect of eating on the uptake of PSMA ligands in the salivary glands.

ABSTRACT:

Rationale

PSMA-directed therapy for metastatic prostate cancer is gaining adoption as a treatment option. However, accumulation of ¹⁷⁷Lu/²²⁵Ac-PSMA in the salivary glands remains a problem, with risk of dose-limiting xerostomia and potentially severe effect on the quality of life. Gustatory stimulation is an approach that has commonly been used in radioactive iodine therapy to reduce accumulation in the salivary glands. However, based on theoretical differences in biodistribution, it was hypothesized that this could potentially lead to adverse increased toxicity for PSMA-ligand therapy. The primary objective of this work was to determine if gustatory stimulation by eating an assortment of sweet/fatty/acidic foods during the biodistribution phase of [¹⁸F]DCFPyl could result in a clinically relevant (> 30%) change in the uptake of the tracer in the salivary glands.

Methods

10 patients who already received a whole-body [¹⁸F]DCFPyl PET/CT scan for evaluation of prostate cancer, underwent a repeat (intervention) PET/CT scan within a month of the first (control) scan. During the intervention scan, patients chose from an assortment of sweet/fatty/acidic foods, which they then chewed and swallowed for a period of time starting 1 min before tracer administration to 10 min thereafter. Data from both scans were analyzed by placing VOIs on the major salivary glands and segmenting them using relative thresholds.

Results

A slight increase in PSMA uptake in the parotid glands was observed on the intervention scan when compared to the baseline scan (+ 7.1% SUL_mean and + 9.2% SUL_max, p < 0.05). No significant difference in PSMA uptake in the submandibular glands was seen.

Conclusions

Eating only slightly increases uptake of [¹⁸F]DCFPyl in the parotid glands. We nonetheless recommend refraining from gustatory stimulation during the administration and early biodistribution phase of radionuclide therapy with PSMA-ligands to reduce the risk of avoidable additional toxicity.

SUBMITTER: Mohan V

PROVIDER: S-EPMC8473516 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:AimTo investigate whether modifications of prostate-specific membrane antigen (PSMA)-targeted radiolabeled urea-based inhibitors could reduce salivary gland uptake and thus improve tumor-to-salivary gland ratios, several analogs of a high affinity PSMA ligand were synthesized and evaluated in in vitro and in vivo studies.MethodsBinding motifs were synthesized 'on-resin' or, when not practicable, in solution. Peptide chain elongations were performed according to optimized standard protocols via solid-phase peptide synthesis. In vitro experiments were performed using PSMA+ LNCaP cells. In vivo studies as well as ?SPECT/CT scans were conducted with male LNCaP tumor xenograft-bearing CB17-SCID mice.ResultsPSMA ligands with A) modifications within the central Zn2+-binding unit, B) proinhibitor motifs and C) substituents & bioisosteres of the P1'-?-carboxylic acid were synthesized and evaluated. Modifications within the central Zn2+-binding unit of PSMA-10 (Glu-urea-Glu) provided three compounds. Thereof, only natLu-carbamate I (natLu-3) exhibited high affinity (IC50?=?7.1?±?0.7?nM), but low tumor uptake (5.31?±?0.94% ID/g, 1?h p.i. and 1.20?±?0.55% ID/g, 24?h p.i.). All proinhibitor motif-based ligands (three in total) exhibited low binding affinities (>?1??M), no notable internalization and very low tumor uptake (<?0.50% ID/g). In addition, four compounds with P1'-?-carboxylate substituents were developed and evaluated. Thereof, only tetrazole derivative natLu-11 revealed high affinity (IC50?=?16.4?±?3.8?nM), but also this inhibitor showed low tumor uptake (3.40?±?0.63% ID/g, 1?h p.i. and 0.68?±?0.16% ID/g, 24?h p.i.). Salivary gland uptake in mice remained at an equally low level for all compounds (between 0.02?±?0.00% ID/g and 0.09?±?0.03% ID/g), wherefore apparent tumor-to-submandibular gland and tumor-to-parotid gland ratios for the modified peptides were distinctly lower (factor 8-45) than for [177Lu]Lu-PSMA-10 at 24?h p.i.ConclusionsThe investigated compounds could not compete with the in vivo characteristics of the EuE-based PSMA inhibitor [177Lu]Lu-PSMA-10. Although two derivatives (3 and 11) were found to exhibit high affinities towards LNCaP cells, tumor uptake at 24?h p.i. was considerably low, while uptake in salivary glands remained unaffected. Optimization of the established animal model should be envisaged to enable a clear identification of PSMA-targeting radioligands with improved tumor-to-salivary gland ratios in future studies.